Developer of pharmaceuticals designed to target all stages of the hepatitis B virus. The company has nuclecapsid inhibitor, RNA destabilizer and immunomodulator projects in the pipeline, enabling healthcare professionals to prescribe better treatments to patients.
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
4. Later Stage VC (Series B) | 08-Nov-2021 | $54.6M | 00000 | 00000 | Completed | Clinical Trials - Phase 1 |
3. Later Stage VC (Series A) | 06-Nov-2020 | 000.00 | 000.00 | Completed | Clinical Trials - Phase 1 | |
2. Early Stage VC | 11-Nov-2019 | $14.2M | $14.2M | Completed | Clinical Trials - Phase 1 | |
1. Early Stage VC | 05-Feb-2018 | Completed | Startup |
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Advantech Capital Partners | Growth/Expansion | Minority | 000 0000 | 000000 0 | |
Co-Stone Capital | PE/Buyout | Minority | 000 0000 | 000000 0 | |
Dawu Venture Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
DYEE Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
Fellow Partners | Venture Capital | Minority | 000 0000 | 000000 0 |